# Michael Shih

> Michael Shih is the Chief Executive Officer of NeoPhore Ltd, a London-based small molecule neoantigen immuno-oncology company developing first-in-class drugs that target the DNA mismatch repair (MMR) pathway to make cancers more visible to the immune system. An attorney by training with degrees in biology, he spent nearly two decades structuring biotech deals before sitting in the chief executive's chair, with senior business development and corporate development roles at Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics and Eisai. He took the helm at NeoPhore in December 2024, right after the company closed an oversubscribed Series B round backed by Bristol Myers Squibb.

- **Role:** Chief Executive Officer at NeoPhore Ltd
- **Organizations:** NeoPhore Ltd, Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics, Eisai
- **Nationality:** American
- **Education:** B.S., Molecular Biology, Cornell University, M.S., Biology, University of Illinois at Urbana-Champaign, J.D., Fordham University School of Law
- **Known for:** Appointed CEO of NeoPhore in December 2024, immediately following an oversubscribed Series B financing supported by Bristol Myers Squibb, Nearly 20 years of experience in business development, licensing and M&A across pharma and biotech, Led business development at Kite Pharma and headed business development at Biogen

## Career timeline

- **2015** — Joined Kastle Therapeutics as Vice President, Business Development and Chief Legal Counsel
- **earlier** — Vice President of Business Development at Epizyme
- **earlier** — Senior Director of Business Development at Forest Laboratories
- **earlier** — Business development and in-house legal counsel roles at Eisai
- **later** — Vice President and Head of Global Transactions at Sanofi
- **later** — Senior Vice President, Head of Business Development at Biogen
- **later** — Vice President of Corporate Development at Kite Pharma
- **2024** — Appointed Chief Executive Officer and Board member of NeoPhore (Dec 16, 2024)
- **2025** — Presented at the Morgan Stanley 23rd Annual Global Healthcare Conference (Sept 2025)

## Achievements

- Appointed CEO of NeoPhore in December 2024, immediately following an oversubscribed Series B financing supported by Bristol Myers Squibb
- Nearly 20 years of experience in business development, licensing and M&A across pharma and biotech
- Led business development at Kite Pharma and headed business development at Biogen
- Headed global transactions at Sanofi

## Latest updates

- **2024-12** — Named Chief Executive Officer and board member of NeoPhore
- **2025-09** — Presented as NeoPhore CEO at the Morgan Stanley 23rd Annual Global Healthcare Conference

## Links

- Website: https://neophore.com
- LinkedIn: http://www.linkedin.com/in/mshih

---

Profile page: https://yespress.io/michael-shih
Published by YesPress — https://yespress.io
Last updated: 2026-06-20